MedPath

Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)

Recruiting
Conditions
Vaso-occlusive Crisis
Sickle Cell Disease
Registration Number
NCT05376046
Lead Sponsor
BILLOIR
Brief Summary

Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin S (HbS) which polymerises in red blood cell (RBC) at deoxygenated state. SCD is associated with chronic haemolytic anaemia, vaso-occlusive crisis (VOC) leading to frequent hospitalisation.

The aim of the study was to to investigate whether a combination of routine laboratory biomarkers of haemolysis could be used to predict VOC development in confirmed SCD patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Sickle cell disease
Exclusion Criteria
  • <18 years
  • pregnancy
  • Patient under protective guardianship or curatorship

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hospitalisation for Vaso-occlusive crisis within one years1 year

Following injury consultation, evaluation of biological markers predicting vaso-occlusive crisis requiring hospitalisation in the year

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Rouen university Hospital

🇫🇷

Rouen, France

Rouen university Hospital
🇫🇷Rouen, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.